The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
If the company has any news/data, etc then it must report this to the market via an RNS.
This is the law!
So, in short, they don’t have the news/data, yet.
These trials often run way over, so don’t panic.
Doc
Interesting and shrewd spot.
Hope you’re well.
Watching from afar and hoping that DD brings us hope and joy at the Conference.
ATB
Thanks trinity - top man!
Excellent post.
Uncrossing trade happens when the stock market closes - @4.35pm
Just green bin folks.
Much easier.
Burstead obviously had no attention as a child.
Sorry state of affairs, really.
TtB
ATB
The SOC across the different hospitals was questionable and fluctuated in the different countries.
Deep dive is currently happening and recovery is hopefully possible.
Nevertheless, don’t want to cross talk another stock as that wasn’t my intention, but thought it was worth mentioning to keep feet on the ground and hopefully SP will keep going up for investors.
ATB
As I say, I wish investors all the best but let’s go for £1.50 and then £2, first.
Where do people just randomly get £80 from?
Mcap of billions.
GLA
Axe
I must get myself one of those crystal balls too.
Tommy
It appears that in many hospitals the SOC was a ****show and clearly the quality and efficiency across the various hospitals was wide ranging.
I don’t know what Synairgen could have done to impact/control/improve this as the number of hospitals involved were plenty?
Surely, this was the responsibility or the individual hospitals to deliver the required SOC?
Can some of the data can be written off and placed down to SOC issues?
ATB
A word of warning.
This very same thing happened on the Synairgen board a.few months back. Ridiculous figures being thrown around when the price was at £2.
The evidence for a multi bagger was absolutely overwhelming, but despite this, the trial failed to meet its endpoints and the SP crashed to 20p.
I wish everyone success, but also be prepared that nothing is ever a definite on AIM.
Good luck all.
Andy
My concern is that the only people discussing EUA are investors on this board.
So many of us have discussed what if we add A + B + C and then apply for EUA.
Since the dismal Monday RNS, not once have the Company mentioned EUA.
Hence, my concerns.
LPD was 11th November.
Any significant findings from the deep dive, whether positive or negative will need to be reported, via an RNS, immediately. This will be prior to the conference.
Common sense tells you, positive findings will have a positive impact on the SP, negative and it will nosedive.
Financials will be reported, as Tommy stated, towards the end of next month.
SNG
We had a lengthy discussion on this a while ago.
Vaccinations do affect menstruation cycles. I raised it at the time as my missus was experiencing the same symptoms you stated.
Severity of illness was bizarre in our household. My missus had a severe chest infection, despite her immunity normally being rock solid from working in hospitals, whereas I had very mild symptoms. We were both fully vaccinated and boostered.
SNG
I have to agree on the vaccines narrative, as it’s a discussion that I’ve been involved in more and more.
Also, yes the American market was always the target; fingers crossed that we do better this time.
ATB
Mr Costs
Yes, you are being negative with that comment.
How could they have set up anything before the results of the P3?
RM stated that he was in discussions, networking, etc.
This time, the P3 has been completed, so are we hoping for a different outcome?
ATB
Good post Trinity.
Should the deep dive and A2 data unearth any gems you need to factor in Polygon too.
What will their strategy be, should this happen?
Also, only my opinion, but I don’t think the Synairgen team have enough clout or expertise to bring this to market without a JV.
ATB
It’s the timelines that the market doesn’t like, imo.
If you know there will be important news in 5 weeks, why would you invest now unless you are planning to build a position.
How do you suggest they do that?
There can’t be any sales as we don’t have approval for the drug to be used, yet.
There is no volume as the recent RM video tells a timeline of mid May.
Unless you are building a position, I would imagine that most investors will get involved just prior to the conference and unblinding of the deep dive data.